VALN - Pfizer Valneva complete enrollment in mid-stage trial for Lyme disease vaccine candidate

Diy13/iStock via Getty Images Pfizer (PFE) and Valneva (VALN) have completed the recruitment of subjects in a Phase 2 trial for VLA15, a vaccine candidate targeting Lyme disease. In the randomized, observer-blind, placebo-controlled trial, 625 participants aged 5 – 65 years will receive either VLA15 or placebo. The VLA15-221 study aims to evaluate the safety and immunogenicity of VLA15 and select the optimal vaccination schedule for the Phase 3 trial. Topline data are expected in 1H 2022. “The main safety and immunogenicity readout will be performed approximately one month after completion of the primary vaccination schedule (i.e. at Month 7),” the companies said in the announcement. Valneva, which develops VLA15 in collaboration with Pfizer, received $10M of milestone payment in Q2 2021 from the U.S. pharma giant in connection with the start of the Phase 2 trial.

For further details see:

Pfizer, Valneva complete enrollment in mid-stage trial for Lyme disease vaccine candidate